Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 ...

Investing.com -- Shares of Allakos Inc . (NASDAQ: ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of therapeutic ...

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...

Investing.com -- Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of ...